Skip to content

Insider · CIK 0001566083

Karen Prange

director

Files at ATRC (AtriCure, Inc.), NVRO (NEVRO CORP), EMBC (Embecta Corp.). First filing Mar 7, 2025, latest Mar 7, 2025.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $233k sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

ATRC: AtriCure, Inc.

ATRCOct 9, 2026 · close 55.81

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
38Weak
ATRCsell
AtriCure, Inc.
$233k
6,100 shares
-25%-

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
May 19, 2025ATRC
AtriCure, Inc.
AGrant or award
Common Stock
+5,401$0.00$023,229May 21, 2025
Apr 3, 2025NVRO
NEVRO CORP
DDisposition to issuer
Common Stock
-33,948--0Apr 3, 2025
Mar 5, 2025ATRC
AtriCure, Inc.
SOpen-market sale
Common Stock
-6,100$38.12$233k17,828Mar 7, 2025
Feb 12, 2025EMBC
Embecta Corp.
AGrant or award
Common Stock
+13,839$0.00$039,743Feb 14, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Karen Prange: insider trades and track record | InsiderTell